Eflornithine cream

BNF:
13.9
Status:
Grey, Grey - after consultant/specialist recommendation
Decision Date:
None
 

Comments

GREY specialist recommendation as per NHSE Service spec: Gender Identity Services for Adults. This should be done in close collaboration with the specialists at the Gender Identity Clinics. (Decision date - July 2023)

GREY: for facial hirsutism in women (decision date - Dec 2015, Nov 2019). Before considering eflornithine cream:

  1. Women who are overweight or obese should be encouraged to lose weight
  2. Check underlying cause as hirsutism may result from serious medical conditions or from medications (e.g. ciclosporin, glucocorticoids or minoxidil) 
  3. The primary option for the majority of women with hirsutism is self-funded cosmetic treatments for reduction of hair growth or removal (e.g. shaving, plucking, laser treatment or electrolysis)
  4. Eflornithine should only be considered for use in women after failures of self-care and lifestyle measures, where alternative drug therapy e.g. co-cyprindiol, is ineffective, not recommended, contra-indicated or considered inappropriate.
  5. Treatment with eflornithine does not remove hairs but slows down hair growth such that users require less frequent hair removal by other methods
  6. Treatment should be discontinued if no effects are seen within 4 months

Grey Drug Classifications

  • 1: Lack of data on effectiveness compared with standard therapy
  • 5: Less cost-effective than current standard therapy

Grey Drug Classifications

  • 1: Lack of data on effectiveness compared with standard therapy
  • 5: Less cost-effective than current standard therapy

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app